Description
+ Include: 24 videos + 25 pdfs, size: 1.87 GB
+ Target Audience: oncologist
+ Sample video: contact me for sample video
+ Information:
- Start date 09 Jun 2023
- End date 10 Jun 2023
- Location Barcelona, Spain
Learning objectives
- To understand the function and biology of the most relevant driver molecular alterations in early and metastatic breast cancer
- To gain insights in the spectrum of breast cancer molecular aberrations, platforms and strategies for molecular testing
- To provide information and in-depth discussion on the state-of-the-art and emerging therapeutic strategies integrating major germinal or somatic mutations driving oncogene addiction in early and metastatic breast cancer
- To present novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of metastatic breast cancer
+ Topics:
Programme.pdf
Session 1 A Clinicopathological Case Presented and Discussed by a Molecular Tumour Board.mp4
Session 1 A Clinicopathological Case Presented and Discussed by a Molecular Tumour Board.pdf
Session 1 ER Biology of the Target Biomarker.mp4
Session 1 ER Biology of the Target Biomarker.pdf
Session 1 ESR1 Mutations Testing for the Target Biomarker (Assays, Technicalities and Practicalities, Challenges for Interpretation).mp4
Session 1 ESR1 Mutations Testing for the Target Biomarker (Assays, Technicalities and Practicalities, Challenges for Interpretation).pdf
Session 1 Update on the Clinical Efficacy of Targeted Agents Indications, Efficacy and Toxicity.mp4
Session 1 Update on the Clinical Efficacy of Targeted Agents Indications, Efficacy and Toxicity.pdf
Session 2 A Clinicopathological Case Presented and Discussed by a Molecular Tumour Board.mp4
Session 2 A Clinicopathological Case Presented and Discussed by a Molecular Tumour Board.pdf
Session 2 Testing for the Target Biomarker (Assays, Technicalities and Practicalities, Challenges for Interpretation).mp4
Session 2 Testing for the Target Biomarker (Assays, Technicalities and Practicalities, Challenges for Interpretation).pdf
Session 2 The PI3K Pathway Insights into the Biology and Clinical Research.mp4
Session 2 The PI3K Pathway Insights into the Biology and Clinical Research.pdf
Session 2 Value Health Economics of Testing and Targeting (Incl. MCBS, ESCAT Actionability, RWD) for ESR1, PIK3CA and AKT.mp4
Session 2 Value Health Economics of Testing and Targeting (Incl. MCBS, ESCAT Actionability, RWD) for ESR1, PIK3CA and AKT.pdf
Session 3 A Clinicopathological Case Presented and Discussed by a Molecular Tumour Board.mp4
Session 3 A Clinicopathological Case Presented and Discussed by a Molecular Tumour Board.pdf
Session 3 Biology of the Target Biomarker.mp4
Session 3 Biology of the Target Biomarker.pdf
Session 3 Testing for the Target Biomarker (Assays, Technicalities and Practicalities, Challenges for Interpretation).mp4
Session 3 Testing for the Target Biomarker (Assays, Technicalities and Practicalities, Challenges for Interpretation).pdf
Session 3 Update on the Clinical Efficacy of Targeted Agents Indications, Efficacy and Toxicity.mp4
Session 3 Update on the Clinical Efficacy of Targeted Agents Indications, Efficacy and Toxicity.pdf
Session 4 A Clinicopathological Case Presented and Discussed by a Molecular Tumour Board.mp4
Session 4 A Clinicopathological Case Presented and Discussed by a Molecular Tumour Board.pdf
Session 4 Biology and Testing of Biomarkers for Targeted Therapy in TNBC.mp4
Session 4 Biology and Testing of Biomarkers for Targeted Therapy in TNBC.pdf
Session 4 Update on the Clinical Efficacy of Targeted Agents Indications, Efficacy and Toxicity.mp4
Session 4 Update on the Clinical Efficacy of Targeted Agents Indications, Efficacy and Toxicity.pdf
Session 4 Value Health Economics of Testing and Targeting (Incl. MCBS, ESCAT Actionability, RWD) for PDL1, BRCA, KI67 and TILs.mp4
Session 4 Value Health Economics of Testing and Targeting (Incl. MCBS, ESCAT Actionability, RWD) for PDL1, BRCA, KI67 and TILs.pdf
Session 5 HER2 Low Disease Clinical Trials and Challenges in Testing.mp4
Session 5 HER2 Low Disease Clinical Trials and Challenges in Testing.pdf
Session 5 HER2 Pathway Testing HER2 Expression and HER2 Mutations.mp4
Session 5 HER2 Pathway Testing HER2 Expression and HER2 Mutations.pdf
Session 5 Update on the Clinical Treatment Algorithm in HER2 Positive Disease (Early and Metastatic).mp4
Session 5 Update on the Clinical Treatment Algorithm in HER2 Positive Disease (Early and Metastatic).pdf
Session 5 Value Health Economics of Testing and Targeting (Incl. MCBS, ESCAT Actionability, RWD).mp4
Session 5 Value Health Economics of Testing and Targeting (Incl. MCBS, ESCAT Actionability, RWD).pdf
Session 6 Integrating NGS in Treatment Selection for Metastatic Breast Cancer (Solid Biopsy vs ctDNA).mp4
Session 6 Integrating NGS in Treatment Selection for Metastatic Breast Cancer (Solid Biopsy vs ctDNA).pdf
Session 6 Role of Genomic Assays in Early Breast Cancer.mp4
Session 6 Role of Genomic Assays in Early Breast Cancer.pdf
Session 6 Role of Genomic Assays in Metastatic Setting A Focus on Immunotherapy.mp4
Session 6 Role of Genomic Assays in Metastatic Setting A Focus on Immunotherapy.pdf
Welcome and Learning Objectives Introduction.mp4
Welcome and Learning Objectives Introduction.pdf
Reviews
There are no reviews yet.